Preventing Viral Disease

PeptiVir is an early stage biopharmaceutical company focused on the development and commercialization of a conformationally-constrained, synthetic peptide-based vaccine platform for the prevention of viral diseases. 

PeptiVir’s lead product, PVI-1000, has the potential to be a “universal” influenza vaccine wherein one or two administrations could lead to sustained protection against multiple seasonal and pandemic strains. This is in contrast to existing influenza vaccines that must be generated and administered yearly and induce antibodies that provide protection only against that year’s seasonal flu strains. 

PVI-1000 is predicted to work by inducing cross-reactive antibodies that would protect against multiple influenza virus strains.